Calamos Advisors
JAZZ icon

Calamos Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Calamos Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$345K Sell
1,431
-206
-13% -$45.1K ﹤0.01% 862
2026
Q1 		$309K Buy
+1,637
New +$286K ﹤0.01% 990
2023
Q2 		– Sell
-43,770
Closed -$6.4M – 1034
2023
Q1 		$6.4M Sell
43,770
-546
-1% -$80.8K 0.03% 563
2022
Q4 		$7.06M Buy
44,316
+179
+0.4% +$26.2K 0.03% 572
2022
Q3 		$5.88M Buy
44,137
+127
+0.3% +$19.3K 0.03% 636
2022
Q2 		$6.87M Sell
44,010
-925
-2% -$142K 0.03% 612
2022
Q1 		$7M Buy
+44,935
New +$6.52M 0.03% 617
2021
Q3 		– Sell
-16,940
Closed -$3.01M – 1014
2021
Q2 		$3.01M Buy
+16,940
New +$2.93M 0.01% 658
2017
Q2 		– Sell
-68,409
Closed -$9.93M – 628
2017
Q1 		$9.93M Sell
68,409
-139,523
-67% -$18.2M 0.08% 286
2016
Q4 		$22.7M Buy
207,932
+29,939
+17% +$3.33M 0.18% 165
2016
Q3 		$21.6M Buy
177,993
+58,889
+49% +$7.94M 0.15% 184
2016
Q2 		$16.8M Sell
119,104
-69,941
-37% -$10.3M 0.12% 218
2016
Q1 		$24.7M Buy
189,045
+60,489
+47% +$7.53M 0.16% 178
2015
Q4 		$18.1M Buy
128,556
+15,573
+14% +$2.16M 0.11% 201
2015
Q3 		$15M Buy
112,983
+4,455
+4% +$767K 0.1% 216
2015
Q2 		$19.1M Buy
108,528
+104,828
+2,833% +$18.8M 0.12% 200
2015
Q1 		$639K Buy
3,700
+800
+28% +$137K ﹤0.01% 572
2014
Q4 		$475K Sell
2,900
-190,531
-99% -$31.6M ﹤0.01% 607
2014
Q3 		$31.1M Sell
193,431
-217,036
-53% -$33.4M 0.21% 133
2014
Q2 		$60.3M Sell
410,467
-140,023
-25% -$19.4M 0.38% 74
2014
Q1 		$76.3M Sell
550,490
-1,441
-0.3% -$217K 0.49% 49
2013
Q4 		$69.9M Sell
551,931
-631,297
-53% -$65.3M 0.44% 57
2013
Q3 		$109M Sell
1,183,228
-5,374
-0.5% -$434K 0.68% 38
2013
Q2 		$81.7M Buy
+1,188,602
New +$72.7M 0.53% 53

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Calamos Advisors's JAZZ Position: Q2 2026 in Review

Calamos Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 13% in Q2 2026, selling an estimated $45.1K and leaving 1,431 shares worth $345K. The position accounts for ﹤0.01% of the portfolio, ranked #862.

Calamos Advisors first reported a position in JAZZ in Q2 2013 and has held it in 24 quarters since. The position peaked at $109M in Q3 2013. 645 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Calamos Advisors held 1,431 shares of Jazz Pharmaceuticals worth $345K as of Q2 2026.
  • Calamos Advisors sold 206 Jazz Pharmaceuticals shares in Q2 2026, an estimated $45.1K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #862 holding.
  • Calamos Advisors first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • Calamos Advisors's Jazz Pharmaceuticals position peaked at $109M in Q3 2013.
  • 645 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.